Start Here
BPC-157 vs TB-500: what's the real difference?
BPC-157 and TB-500 are two of the most searched recovery peptides in the wellness and longevity space — and two of the most frequently confused. People considering peptide therapy for injury recovery, joint health, or general resilience often ask which one they need, or whether they should use both. The honest answer: they are related tools with different profiles, and the right choice depends entirely on the individual. This page compares them to help you choose; if you are asking about taking both together, see the Wolverine Stack (BPC-157 + TB-500).
This guide walks through what each peptide is, how BPC-157 and TB-500 differ in their proposed mechanisms, who tends to be a candidate, and what supervised use actually involves. It is educational information, not medical advice — peptides are not a do-it-yourself category, and suitability should always be determined case by case with a qualified provider.
At Protocol Health, a family-owned, physician-led clinic in Scarsdale, New York, we see patients in person at our Scarsdale clinic and by telehealth in New York, New Jersey, Connecticut, Florida and California. Peptide therapy here starts with a consultation and, where relevant, lab work, and it is always clinician-supervised, never a self-guided experiment.
Explore the Wolverine Recovery StackQuick Answer
The difference in one paragraph
In one paragraph, the difference is that BPC-157 is most associated with local tissue repair and TB-500 with systemic, whole-body effects. BPC-157 (a synthetic peptide derived from a protein found in gastric juice) is most associated with localized tissue repair (tendon, ligament, muscle, and gut lining) and is often discussed for site-specific recovery. TB-500 (a synthetic fragment related to the protein thymosin beta-4) is more associated with systemic, whole-body effects on cell migration, flexibility, and circulation.
In plain terms: BPC-157 is generally framed as the more targeted, local-repair peptide, while TB-500 is framed as the broader, systemic one. Some protocols combine them precisely because their proposed mechanisms are thought to complement each other — the pairing many people refer to as a recovery stack.
Neither is an FDA-approved drug, and neither is intended to diagnose, treat, cure, or prevent any disease. Neither has ever been FDA-approved for any use, so prescribing either is unapproved use rather than off-label use, which is exactly why physician oversight matters.
The Basics
What is BPC-157?
BPC-157 stands for Body Protection Compound-157. It is a synthetic, stable peptide based on a sequence identified in human gastric juice. In preclinical and animal research, it has been studied for a possible role in supporting the repair of connective tissue, muscle, and the gastrointestinal lining, and for effects on new blood-vessel formation (angiogenesis) that may support healing.
Because much of the interest centers on tendons, ligaments, and gut tissue, BPC-157 tends to come up in conversations about localized soft-tissue recovery, joint discomfort, and gut resilience. People exploring it often do so alongside physical therapy, training modifications, or other recovery work rather than in place of them.
It is important to be clear-eyed: robust, large-scale human clinical trials for BPC-157 remain limited, and much of the current evidence base is preclinical. That does not make it meaningless — it makes careful, individualized provider guidance essential and realistic expectations non-negotiable.
The Basics
What is TB-500?
TB-500 is a synthetic version of a fragment of thymosin beta-4, a naturally occurring protein present in nearly all human cells and especially concentrated in platelets and wound fluid. Thymosin beta-4 plays a role in regulating actin, a protein central to how cells move, build structure, and migrate to areas that need repair.
Because of this, TB-500 is generally discussed as a more systemic peptide — one whose proposed effects on cell migration and blood-vessel formation are thought to act across the body rather than at a single injection site. That systemic framing comes from research on the parent protein and has not been tested for TB-500 in people. It comes up in conversations about overall recovery capacity and resilience after physical stress.
As with BPC-157, the human clinical data is limited. TB-500 has never been FDA-approved for any use, and its use should always be framed as physician-supervised and individualized.
Head To Head
How do BPC-157 and TB-500 actually differ?
BPC-157 and TB-500 differ most clearly as local versus systemic peptides. BPC-157 is most often associated with targeted, site-specific tissue repair and gut support. TB-500 is most often associated with broader, whole-body effects on cellular movement. That distinction is a useful mental model, even though biology is rarely so tidy.
Their origins differ too. BPC-157 traces to a compound found in gastric juice and is frequently studied in a connective-tissue and gastrointestinal context. TB-500 derives from thymosin beta-4, a protein tied to cellular structure and migration throughout the body. Different starting points, different emphasis.
They also differ in how they are commonly used. BPC-157 protocols may emphasize a specific area of concern, while TB-500 is framed around general recovery capacity. This complementary framing is why the two are sometimes combined into a single supervised recovery protocol rather than viewed as competitors.
What they share matters as much as what separates them: both are synthetic peptides, neither is FDA-approved for any use, both lack large-scale human trials, and both should only be considered under qualified medical supervision with realistic, evidence-aware expectations.
The evidence
BPC-157 vs TB-500: what does the evidence say?
The evidence on BPC-157 vs TB-500 says neither peptide has strong human support, and the local-versus-systemic framing above is a clinical rule of thumb rather than something trials have tested. A 2026 scoping review in the American Journal of Sports Medicine looked at both, along with four other popular peptides (Tewari et al., 2026). About two-thirds of the publications were animal studies. Human studies were few and mostly lacked robust controls, and the authors concluded that claimed recovery benefits remain unsubstantiated in human trials.
BPC-157 has slightly more musculoskeletal-specific work. A 2025 systematic review of 36 studies found better healing in animal models of muscle, tendon, ligament and bone injury, one small human study of knee pain, and no clinical safety data in humans (Vasireddi et al., 2025).
TB-500's support comes mostly from research on its parent protein, thymosin beta-4, including phase 2 trials in chronic skin ulcers, not sports injuries. See what is TB-500 and what is BPC-157 for the detail on each. In short, the evidence for both peptides is mostly animal data, with very little from human trials.
| BPC-157 | TB-500 | |
|---|---|---|
| Based on | Fragment of a protein in gastric juice | Short region of thymosin beta-4 |
| Most studied for | Tendon, ligament, muscle, gut lining (animals) | Cell migration, wound healing (mostly parent protein) |
| Usual framing | Local, site-specific repair | Broader, whole-body recovery |
| Human evidence | One small knee-pain study | Phase 2 skin-ulcer trials of thymosin beta-4, not TB-500 |
| FDA status | Not FDA-approved | Not FDA-approved |
| Sports status | On the WADA prohibited list | On the WADA prohibited list |
Is It Right For Me
Who is a candidate — and what about safety?
Not everyone is a candidate for peptide therapy, and safety is a real question because human safety data is limited. Adults exploring recovery support (often active people, those recovering from soft-tissue strain, or those focused on longevity and resilience) sometimes ask about these peptides. Whether either is appropriate depends on your health history, current medications, goals, and lab work, which is why a consultation comes first.
Because human safety data is limited, responsible use means honest conversations about what is and isn't known. There is no clinical safety data on BPC-157 in humans, according to the 2025 systematic review, and the FDA says it has not identified any human exposure data for TB-500 (FDA). The FDA has also flagged both, when compounded, for possible immune reactions and peptide-related impurities. Peptides are also not appropriate for certain individuals — including those who are pregnant, nursing, or who have specific health conditions or a history of cancer, where any pro-growth or angiogenic activity warrants extra caution.
Sourcing and quality are a safety issue in their own right. Peptides purchased from unregulated online vendors carry real risks around purity, sterility, and accurate dosing. This is one of the strongest arguments for working within a supervised clinical setting rather than self-treating.
This section is educational and not a substitute for personalized medical advice. A qualified provider should evaluate your suitability case by case.
The Experience
What does supervised peptide therapy involve?
Supervised peptide therapy typically begins with a consultation and, in many cases, baseline lab work so your provider understands your starting point and goals. From there, any protocol is tailored to the individual — there is no universal dose or timeline, and reputable care avoids one-size-fits-all promises.
Ongoing follow-up is part of doing this responsibly. Your clinical team monitors how you're responding, adjusts as needed, and keeps the plan anchored to realistic, evidence-aware expectations rather than hype. Peptides are best understood as one input within a broader recovery and wellness strategy that may include training, sleep, nutrition, and other physician-guided support.
Crucially, expectations should be measured. Peptides may support recovery and resilience for some people, but they are not guaranteed to produce any specific outcome, and they do not replace rest, rehabilitation, or standard medical care when it's needed.
Our Approach
The Protocol Health approach to recovery peptides
At Protocol Health, peptide therapy is always physician-led and individualized, with lab work where it adds information. We don't hand out protocols off a menu. A real clinical team reviews your history, discusses your goals, and determines whether a peptide approach makes sense for you — and, just as importantly, when it doesn't.
For patients whose providers determine a combined recovery approach is appropriate, we offer the Protocol Health Wolverine Stack, a supervised protocol that pairs BPC-157 and TB-500 under clinical oversight. Our Wolverine Stack guide covers what is known about combining them. It is prescribed and monitored, not self-administered from an unknown source. You can explore that option and start a conversation with our team.
The answer to BPC-157 vs TB-500 stays the same: BPC-157 is the better-studied of the two for local tendon, ligament and gut repair in animals, TB-500 rests mostly on research into its parent protein, and no human trial has compared them. Whether either fits your recovery is a decision for a physician who has seen your history.
FAQ
Frequently Asked Questions
Can you take BPC-157 and TB-500 together?
Some supervised protocols do combine them, on the theory that BPC-157's more localized, tissue-repair emphasis and TB-500's more systemic profile complement each other. Whether combining them is appropriate for you is an individual medical decision. Neither is FDA-approved for any use, so both should only be considered under qualified provider supervision.
Which is better for injury recovery, BPC-157 or TB-500?
There is no universal "better" — it depends on the person and the goal. BPC-157 is more often discussed for targeted, site-specific soft-tissue and gut support, while TB-500 is framed around broader, whole-body recovery capacity. Human clinical data is limited for both, so a provider should assess which, if either, fits your situation.
Has any study compared BPC-157 vs TB-500 directly?
Not in humans, as far as published research shows. Reviews in 2025 and 2026 found the evidence for both is mostly from animal studies, with very few controlled human studies of either. Choosing between them is therefore a clinical judgment about your injury and goals, not a choice backed by comparative trials.
Are BPC-157 and TB-500 FDA approved?
No. Neither is an FDA-approved drug, and neither is approved to diagnose, treat, cure, or prevent any disease. Neither has an FDA-approved version for any use. This is educational information, not medical advice, and any use should be physician-supervised and individualized.
Are these peptides safe?
Their safety in people is largely unknown: a 2025 systematic review found no clinical safety data for BPC-157, and the FDA reports no identified human exposure data for TB-500. Safety also depends heavily on sourcing, sterility, and accurate dosing, which is why supervised clinical use is strongly preferable to self-treatment. A provider should evaluate your suitability case by case.
How are these peptides administered?
In a supervised setting, recovery peptides are typically given by subcutaneous injection under a provider-directed protocol. Specific dosing and timing are individualized rather than standardized. Because quality and sterility matter so much, administration should happen through a legitimate clinical channel, not products bought from unregulated vendors.
Do I need lab work before starting peptide therapy?
In many cases, yes. Baseline labs help your provider understand your health status, tailor any protocol, and monitor your response over time. At Protocol Health, peptide therapy begins with a consultation, with labs where they add information, to determine whether it's appropriate for you.
Explore